Back to the febrile neutropenia management series. Two questions frequently arise during the course of management, particularly with regards to febrile neutropenia (FN) in patients with haematological malignancies where the duration of neutropenia may be very long: In the presence of neutropenia, can there be “de-escalation” of antibiotic therapy if a sensitive bacterium is cultured […]

After the rates of Pseudomonas aeruginosa infections fell in patients with febrile neutropenia, it became tacit knowledge to many oncologists (and haematologists) that the majority of patients with febrile neutropenia – especially those with solid organ cancers – recovered uneventfully. How could this knowledge be codified into a predictive model that could reliably separate out patients at […]

Chemotherapy-induced febrile neutropenia is a life-threatening condition that remains common during the therapy of haematological malignancies, but has become far rarer for patients with solid tumours because of the increased use of targeted therapy. It is traditionally defined as a single oral temperature of 38.3ºC or a temperature of greater than 38.0ºC sustained for more […]